Literature DB >> 25266809

Vancomycin nephrotoxicity: a review.

Kari A Mergenhagen1, Angela R Borton2.   

Abstract

Vancomycin earned notoriety for its tendency to cause nephrotoxicity shortly after it was introduced into practice, though the impurities responsible for historically significant rates of nephrotoxicity are of minimal concern today. Increasing usage of vancomycin has provided evidence that the drug itself can be nephrotoxic, but the exact mechanism by which this occurs has not been determined. Various studies have identified risk factors associated with development of vancomycin-associated nephrotoxicity, including total daily dose > 4 grams, trough levels > 20 mg/L, therapy exceeding 6 days, concurrent use of other nephrotoxic agents, preexisting renal disease, obesity, hypotensive episodes, and increasing severity of illness. Preventative strategies beyond risk assessment and therapeutic drug monitoring have shown little promise. Most cases of nephrotoxicity are reversible with discontinuation of vancomycin, but permanent renal damage can occur. This article is intended to serve as a practical review of vancomycin-associated nephrotoxicity, including historical context, risk factors, and common methods to evaluate and define renal dysfunction.
© The Author(s) 2014.

Entities:  

Keywords:  nephrotoxicity; therapeutic drug monitoring; vancomycin

Mesh:

Substances:

Year:  2014        PMID: 25266809     DOI: 10.1177/0897190014546114

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  11 in total

1.  Vancomycin in the Kidney-A Novel Cast Nephropathy.

Authors:  M Barry Stokes
Journal:  J Am Soc Nephrol       Date:  2017-03-07       Impact factor: 10.121

2.  Vancomycin-Associated Cast Nephropathy: Reality or Fantasy?

Authors:  Michael B Stokes; Jacob S Stevens
Journal:  Kidney360       Date:  2021-12-01

3.  In Vitro Nephrotoxicity and Permeation of Vancomycin Hydrochloride Loaded Liposomes.

Authors:  Nicole Papp; Jeffin Panicker; John Rubino; Gwendolyn Pais; Alexander Czechowicz; Walter C Prozialeck; Brooke Griffin; Volkmar Weissig; Marc Scheetz; Medha D Joshi
Journal:  Pharmaceutics       Date:  2022-05-28       Impact factor: 6.525

4.  Retracted Article: PVT1 knockdown alleviates vancomycin-induced acute kidney injury by targeting miR-124 via inactivation of NF-κB signaling.

Authors:  Xiaoguang Zhu; Jun Shi; Huicong Li; Fang Chen
Journal:  RSC Adv       Date:  2018-09-12       Impact factor: 4.036

5.  The use of vancomycin in the treatment of adult patients with methicillin-resistant Staphylococcus aureus (MRSA) infection: a survey in a tertiary hospital in China.

Authors:  Jing Tang; Jiali Hu; Lei Kang; Zhengjun Deng; Jiaofen Wu; Jiaqian Pan
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 6.  Kidney biopsy findings in vancomycin-induced acute kidney injury: a pooled analysis.

Authors:  Ioannis Bellos; Vasilios Pergialiotis; Despina N Perrea
Journal:  Int Urol Nephrol       Date:  2021-03-14       Impact factor: 2.370

Review 7.  The 6R's of drug induced nephrotoxicity.

Authors:  Linda Awdishu; Ravindra L Mehta
Journal:  BMC Nephrol       Date:  2017-04-03       Impact factor: 2.388

8.  Mechanisms of LPS-Induced Acute Kidney Injury in Neonatal and Adult Rats.

Authors:  Egor Y Plotnikov; Anna A Brezgunova; Irina B Pevzner; Ljubava D Zorova; Vasily N Manskikh; Vasily A Popkov; Denis N Silachev; Dmitry B Zorov
Journal:  Antioxidants (Basel)       Date:  2018-08-08

9.  Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity.

Authors:  Blanca Humanes; Juan Carlos Jado; Sonia Camaño; Virginia López-Parra; Ana María Torres; Luís Antonio Álvarez-Sala; Emilia Cercenado; Alberto Tejedor; Alberto Lázaro
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

10.  p53 activates miR-192-5p to mediate vancomycin induced AKI.

Authors:  Jinwen Chen; Juan Wang; Huiling Li; Shixuan Wang; Xudong Xiang; Dongshan Zhang
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.